Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Mps1 kinase regulates tumor cell viability via its novel role in mitochondria.

Zhang X, Ling Y, Guo Y, Bai Y, Shi X, Gong F, Tan P, Zhang Y, Wei C, He X, Ramirez A, Liu X, Cao C, Zhong H, Xu Q, Ma RZ.

Cell Death Dis. 2016 Jul 7;7(7):e2292. doi: 10.1038/cddis.2016.193.

2.

Efficient Activation of Apoptotic Signaling during Mitotic Arrest with AK301.

Chopra A, Bond MJ, Bleiler M, Yeagley M, Wright D, Giardina C.

PLoS One. 2016 Apr 20;11(4):e0153818. doi: 10.1371/journal.pone.0153818. eCollection 2016.

3.

SP600125 has a remarkable anticancer potential against undifferentiated thyroid cancer through selective action on ROCK and p53 pathways.

Grassi ES, Vezzoli V, Negri I, Lábadi Á, Fugazzola L, Vitale G, Persani L.

Oncotarget. 2015 Nov 3;6(34):36383-99. doi: 10.18632/oncotarget.5799.

4.

Molecular basis underlying resistance to Mps1/TTK inhibitors.

Koch A, Maia A, Janssen A, Medema RH.

Oncogene. 2016 May 12;35(19):2518-28. doi: 10.1038/onc.2015.319. Epub 2015 Sep 14.

5.

Anthrapyrazolone analogues intercept inflammatory JNK signals to moderate endotoxin induced septic shock.

Prasad KD, Trinath J, Biswas A, Sekar K, Balaji KN, Guru Row TN.

Sci Rep. 2014 Nov 27;4:7214. doi: 10.1038/srep07214.

6.

Dynamic autophosphorylation of mps1 kinase is required for faithful mitotic progression.

Wang X, Yu H, Xu L, Zhu T, Zheng F, Fu C, Wang Z, Dou Z.

PLoS One. 2014 Sep 29;9(9):e104723. doi: 10.1371/journal.pone.0104723. eCollection 2014.

7.

Diaminopyridine-based potent and selective mps1 kinase inhibitors binding to an unusual flipped-Peptide conformation.

Kusakabe K, Ide N, Daigo Y, Itoh T, Higashino K, Okano Y, Tadano G, Tachibana Y, Sato Y, Inoue M, Wada T, Iguchi M, Kanazawa T, Ishioka Y, Dohi K, Tagashira S, Kido Y, Sakamoto S, Yasuo K, Maeda M, Yamamoto T, Higaki M, Endoh T, Ueda K, Shiota T, Murai H, Nakamura Y.

ACS Med Chem Lett. 2012 Jun 6;3(7):560-4. doi: 10.1021/ml3000879. eCollection 2012 Jul 12.

8.

Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic MPS1 kinase inhibitor NMS-P715.

Slee RB, Grimes BR, Bansal R, Gore J, Blackburn C, Brown L, Gasaway R, Jeong J, Victorino J, March KL, Colombo R, Herbert BS, Korc M.

Mol Cancer Ther. 2014 Feb;13(2):307-15. doi: 10.1158/1535-7163.MCT-13-0324. Epub 2013 Nov 26.

9.

Structure-based design of orally bioavailable 1H-pyrrolo[3,2-c]pyridine inhibitors of mitotic kinase monopolar spindle 1 (MPS1).

Naud S, Westwood IM, Faisal A, Sheldrake P, Bavetsias V, Atrash B, Cheung KM, Liu M, Hayes A, Schmitt J, Wood A, Choi V, Boxall K, Mak G, Gurden M, Valenti M, de Haven Brandon A, Henley A, Baker R, McAndrew C, Matijssen B, Burke R, Hoelder S, Eccles SA, Raynaud FI, Linardopoulos S, van Montfort RL, Blagg J.

J Med Chem. 2013 Dec 27;56(24):10045-65. doi: 10.1021/jm401395s. Epub 2013 Dec 2.

10.

Scaffold-focused virtual screening: prospective application to the discovery of TTK inhibitors.

Langdon SR, Westwood IM, van Montfort RL, Brown N, Blagg J.

J Chem Inf Model. 2013 May 24;53(5):1100-12. doi: 10.1021/ci400100c. Epub 2013 May 14.

11.

Cell death signaling and anticancer therapy.

Galluzzi L, Vitale I, Vacchelli E, Kroemer G.

Front Oncol. 2011 May 3;1:5. doi: 10.3389/fonc.2011.00005. eCollection 2011.

12.

The MPS1 family of protein kinases.

Liu X, Winey M.

Annu Rev Biochem. 2012;81:561-85. doi: 10.1146/annurev-biochem-061611-090435. Epub 2012 Apr 5. Review.

13.

Selective killing of p53-deficient cancer cells by SP600125.

Jemaà M, Vitale I, Kepp O, Berardinelli F, Galluzzi L, Senovilla L, Mariño G, Malik SA, Rello-Varona S, Lissa D, Antoccia A, Tailler M, Schlemmer F, Harper F, Pierron G, Castedo M, Kroemer G.

EMBO Mol Med. 2012 Jun;4(6):500-14. doi: 10.1002/emmm.201200228. Epub 2012 Mar 21.

14.

High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors.

Miduturu CV, Deng X, Kwiatkowski N, Yang W, Brault L, Filippakopoulos P, Chung E, Yang Q, Schwaller J, Knapp S, King RW, Lee JD, Herrgard S, Zarrinkar P, Gray NS.

Chem Biol. 2011 Jul 29;18(7):868-79. doi: 10.1016/j.chembiol.2011.05.010.

15.

Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer.

Roylance R, Endesfelder D, Gorman P, Burrell RA, Sander J, Tomlinson I, Hanby AM, Speirs V, Richardson AL, Birkbak NJ, Eklund AC, Downward J, Kschischo M, Szallasi Z, Swanton C.

Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2183-94. doi: 10.1158/1055-9965.EPI-11-0343. Epub 2011 Jul 22.

16.

Two LXXLL motifs in the N terminus of Mps1 are required for Mps1 nuclear import during G(2)/M transition and sustained spindle checkpoint responses.

Zhang X, Yin Q, Ling Y, Zhang Y, Ma R, Ma Q, Cao C, Zhong H, Liu X, Xu Q.

Cell Cycle. 2011 Aug 15;10(16):2742-50. Epub 2011 Aug 15.

17.

Targeting the cell cycle in esophageal adenocarcinoma: an adjunct to anticancer treatment.

Dibb M, Ang YS.

World J Gastroenterol. 2011 Apr 28;17(16):2063-9. doi: 10.3748/wjg.v17.i16.2063. Review.

18.

Quantitative mass spectrometry analysis reveals similar substrate consensus motif for human Mps1 kinase and Plk1.

Dou Z, von Schubert C, Körner R, Santamaria A, Elowe S, Nigg EA.

PLoS One. 2011 Apr 13;6(4):e18793. doi: 10.1371/journal.pone.0018793.

19.

Spindle checkpoint silencing: ensuring rapid and concerted anaphase onset.

Hardwick KG, Shah JV.

F1000 Biol Rep. 2010 Jul 22;2:55. doi: 10.3410/B2-55.

20.

Validating cancer drug targets through chemical genetics.

Burkard ME, Jallepalli PV.

Biochim Biophys Acta. 2010 Dec;1806(2):251-7. doi: 10.1016/j.bbcan.2010.08.002. Epub 2010 Aug 12. Review.

Items per page

Supplemental Content

Write to the Help Desk